Entity

Time filter

Source Type

Tustin, CA, United States

Snell G.,Allergy Immunology and Respiratory Medicine | Herth F.J.F.,Pneumology and Critical Care Medicine | Hopkins P.,Lung Transplant Unit | Baker K.M.,University of Iowa | And 8 more authors.
European Respiratory Journal | Year: 2012

The need for a less invasive procedure than surgical lung volume reduction that can produce consistent improvements with reduced morbidity remains a medical goal in patients with emphysema. We sought to determine the effect of bronchoscopic thermal vapour ablation (BTVA) on lung volumes and outcomes in patients with emphysema. 44 patients with upper lobe-predominant emphysema were treated unilaterally with BTVA. Entry criteria included: age 40-75 yrs, forced expiratory volume in 1 s (FEV 1) 15-45% predicted, previous pulmonary rehabilitation and a heterogeneity index (tissue/air ratio of lower lobe/upper lobe) from high-resolution computed tomography (HRCT) ≥1.2. Changes in FEV 1, St George's Respiratory Questionnaire (SGRQ), 6-min walk distance (6MWD), modified Medical Research Council (mMRC) dyspnoea score, and hyperinflation were measured at baseline, and 3 and 6 months post-BTVA. At 6 months, mean±SE FEV 1 improved by 141±26 mL (p<0.001) and residual volume was reduced by 406±113 mL (p<0.0001). SGRQ total score improved by 14.0±2.4 points (p<0.001), with 73% improving by ≥4 points. Improvements were observed in 6MWD (46.5±10.6 m) and mMRC dyspnoea score (0.9±0.2) (p<0.001 for both). Lower respiratory events (n=11) were the most common adverse event and occurred most often during the initial 30 days. BTVA therapy results in clinically relevant improvements in lung function, quality of life and exercise tolerance in upper lobe predominant emphysema. Copyright©ERS 2012. Source


AMSTERDAM--(BUSINESS WIRE)--Medical technology innovator Uptake Medical announced today that patients with severe emphysema who underwent bronchoscopic lung volume reduction performed with the company’s InterVapor® targeted therapy experienced statistically significant and clinically meaningful benefits in both lung function and quality of life, according to data presented by Prof Dr Med Ralf Eberhardt, an interventional pulmonologist of the Thoraxklinik in Heidelberg, Germany at the European Respiratory Society (ERS) annual meeting in Amsterdam. Prof Eberhardt, an investigator in the STEP-UP clinical study -- a randomized, controlled, multi-center, multi-national trial that involved patients from 13 centers located in Europe and Australia -- reported that InterVapor patients’ FEV1 (lung function) improved 14.7 percent at the six-month mark, while their health-related quality of life (St. George’s Respiratory Quotient or SGRQ-C), showed a 9.7 point improvement. Both of these metrics were statistically significant and exceeded ATS/ERS standards for clinically meaningful improvement. The STEP-UP study was designed to evaluate the safety and performance of the InterVapor system in addition to the optimal medical standard therapy in improving lung performance and quality of life of patients with severe emphysema. The InterVapor system uses heated water vapor to achieve bronchoscopic lung volume reduction in patients with heterogeneous upper lobe emphysema, and was developed by the privately held Uptake Medical. The system recently received Conformité Européene (CE) Mark, allowing commercial sale in Europe. According to Prof Felix Herth, interventional pulmonologist of the Thoraxklinik and co-principal investigator of the STEP-UP study, “The STEP-UP results affirm InterVapor’s safety and effectiveness and represent an important milestone in bronchoscopic intervention. For the first time, we have the option to safely treat patients’ most diseased segments and preserve the less diseased segments, while enhancing both their lung function and quality of life.” Professor Greg Snell, STEP-UP co-principal investigator from The Alfred Hospital in Melbourne, Australia, said, “The gradual natural process of volume reduction that occurs as a result of InterVapor resulted in no pneumothorax in patients 30 days post-treatment. And, since InterVapor requires no implant, patients’ risk of long-term complications is also eliminated. InterVapor is a safe, simple procedure that offers an option to treat severe emphysema patients over time as their disease progresses.” “Uptake Medical is pleased with these promising clinical results, which show that InterVapor plays an important role in offering progressive treatment options for emphysema patients. The technology has now been proven in a randomized clinical trial to improve patients’ lung function and quality of life during the natural progression of this debilitating disease,” said King Nelson, president and CEO of Uptake Medical. Uptake Medical is a privately held company focused on the treatment of lung cancer and emphysema without the risks of surgery and implants or the toxicity of radiation. InterVapor, Uptake’s proprietary targeted vapor ablation technology that received CE Mark approval in 2015, applies energy with heated water vapor via a standard bronchoscope to the lungs. In the 15-minute procedure, lung tissue ablation is performed on the more diseased lung segments. The healthier segments are preserved to provide lung function and quality of life improvements in emphysema patients and to provide potential future targets as the disease inevitably progresses. The InterVapor platform is now being tested and validated as a possible treatment for lung cancer tumors in a first-in-human study of regional lung tumor ablation in patients with early stage lung cancer and lung metastases. The outside-in bronchoscopic approach eliminates the need for percutaneous access or the need to pierce the tumor in a 10-second ablation during a 15-minute procedure. Founded in 2005, Uptake Medical is located in Tustin, California.


TUSTIN, Calif.--(BUSINESS WIRE)--Uptake Medical announced today that it has received CE Mark allowing the commercial sale of its InterVapor system in Europe. InterVapor uses heated water vapor to achieve bronchoscopic lung volume reduction in patients with heterogeneous upper lobe emphysema. According to The Organisation for Economic Co-operation and Development, more than 23 million people in Europe suffer from emphysema, a debilitating and progressive condition that affects the respiratory system1. “The traditional treatment options for severe emphysema patients have been very limited which is why we have remained committed over the past decade to finding a more meaningful treatment alternative for this progressive disease,” said King Nelson, President and CEO of Uptake Medical. “Gaining CE Mark is a major milestone for our company, but more importantly, represents new hope for emphysema patients. We are eager to begin the commercial launch of InterVapor in Europe allowing more interventional pulmonologists to begin using the system in the months ahead.” The CE Mark follows results of the STEP-UP study, a prospective, multi-center, multi-national, randomized-controlled study that was completed in late 2014. STEP-UP, which involved patients from 13 centers in Europe and Australia, was designed to evaluate the safety and performance of the InterVapor system in addition to the optimal medical standard therapy in improving lung performance and quality of life of patients with severe emphysema. The STEP-UP trial results will be reported at the European Respiratory Society meeting in Amsterdam in late September 2015. According to Prof Dr. Med Felix Herth, STEP-UP’s co-principal investigator from ThoraxKlinik in Heidelberg, Germany, “Being granted the CE Mark validates for Uptake Medical the merits of our clinical hypothesis to have for the first time an option where we can treat the most diseased segments and preserve the less diseased segments.” Professor Greg Snell, STEP-UP co-principal investigator from The Alfred Hospital in Melbourne, Australia, said, “InterVapor provides a new way to offer non-surgical treatment to severe emphysema patients over time as the disease progresses.” “InterVapor offers emphysema patients who have exhausted their other medical support options another potential solution to improve their lung function and quality of life, and we look forward to making this technology more widely available to patients across Europe,” Nelson said. Uptake Medical is a privately held company focused on the treatment of lung cancer and emphysema without the risks of surgery and implants or the toxicity of radiation. InterVapor, Uptake’s proprietary targeted vapor ablation technology that received CE Mark approval in 2015, applies energy with heated water vapor via a standard bronchoscope to the lungs. In the 15-minute procedure, lung tissue ablation is performed on the most diseased lung segments. The healthier segments are preserved to provide lung function and quality of life improvements in emphysema patients and to provide potential future targets as the disease inevitably progresses. The InterVapor platform is now being tested and validated as a possible treatment for lung cancer tumors in a first-in-human study of regional lung tumor ablation in patients with early stage lung cancer and lung metastases. The outside-in bronchoscopic approach eliminates the need for percutaneous access or the need to pierce the tumor in a 10-second ablation during a 15-minute procedure. Founded in 2005, Uptake Medical is located in Tustin, California.


News Article | October 9, 2009
Site: www.xconomy.com

Seattle-based Uptake Medical has secured $1.2 million in a second closing of an equity financing, meaning it has raised a total of $4.6 million so far in a round that could be worth as much as $13.3 million if the company achieves certain milestones, says CEO King Nelson. The company is developing a minimally invasive technique for treating chronic lung diseases by using hot vapor to seal off damaged parts of lung so air doesn’t get trapped there. The company is starting larger trials to win clearance to start marketing its device in Europe.


Tuck S.A.,Uptake Medical | Lopes-Berkas V.,American Preclinical Services | Beam S.,Preclinical Pathology Consulting Services | Anderson J.C.,Uptake Medical
International Journal of COPD | Year: 2012

Clinical studies indicate the potential of bronchoscopic thermal vapor ablation to result in clinically relevant improvements in severe chronic obstructive pulmonary disease patients with upper lobe-predominant emphysema. However, the mechanisms by which vapor ablation results in lung volume reduction are not fully known. This study determined the 3-month safety and efficacy of vapor ablation in a canine model of emphysema and described the histopathological changes in the lung. The cranial lobes of papain-exposed dogs were treated with a vapor dose of ten calories per gram of lung tissue (n = 8) or were sham treated (n = 3). Safety was monitored peri- and postoperatively for 3 months. Animals were then sacrificed, estimates of lung volume reduction performed, and the lungs processed for histology. Vapor ablation was associated with an average of 20% volume reduction of the treated lobes and an absence of serious adverse events. The amount of lobar volume reduction was correlated with the amount of fibrosis and atelectasis in the treated lobe. Bronchoscopic thermal vapor ablation at a dose of 10 cal/g results in lobar volume reduction associated with remodeling of the targeted tissue characterized by mature collagen formation in the absence of major adverse events. © 2012 Tuck et al, publisher and licensee Dove Medical Press Ltd. Source

Discover hidden collaborations